tiprankstipranks
Trending News
More News >

InhaleRx Secures Initial Funding to Advance Clinical Trials

Story Highlights
  • InhaleRx Limited has drawn $247,500 from a $38.5M facility to fund clinical trials.
  • The funding supports trials for IRX-211 and IRX-616a, aiming to lead in inhaled therapies.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
InhaleRx Secures Initial Funding to Advance Clinical Trials

Confident Investing Starts Here:

InhaleRx Limited ( (AU:IRX) ) has provided an announcement.

InhaleRx Limited has completed its first drawdown of $247,500 from a $38.5 million funding facility with Clendon Biotech Capital, marking a significant step in its strategic partnership. This funding will support the commencement of clinical trials for IRX-211, a non-opioid treatment for Breakthrough Cancer Pain, and IRX-616a for Panic Disorder, aligning with the company’s goal to become a leader in inhaled therapies for pain and mental health. The partnership with Clendon is seen as crucial for delivering value to shareholders and advancing the company’s clinical development program.

More about InhaleRx Limited

InhaleRx Limited is an Australian clinical stage biotechnology company focused on developing rapid onset, inhaled therapies for unmet medical needs in pain management and mental health sectors. The company aims to achieve U.S. FDA approval through efficient regulatory pathways and is investigating treatments for Breakthrough Cancer Pain and Panic Disorder.

YTD Price Performance: -37.50%

Average Trading Volume: 184,059

Technical Sentiment Signal: Strong Buy

Current Market Cap: A$5.34M

For detailed information about IRX stock, go to TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1